Table 9.
Prevention of T2DM
| Completed trials | Intervention type | Risk reduction (%) | Reference |
|---|---|---|---|
| Da Qing | Diet | 31 | 25 |
| Exercise | 46 | ||
| Diet + exercise | 42 | ||
| Finnish Prevention | Lifestyle | 58 | 189 |
| DPP | Lifestyle | 58 | 24,196 |
| Metformin | 31 | 24,197 | |
| Troglitazone | 75 | 198 | |
| IDDP | Lifestyle | 28.5 | 194 |
| Metformin | 26.4 | ||
| Lifestyle + metformin | 28.2 | ||
| STOP NIDDM | Acarbose | 25 | 109 |
| TRIPOD | Troglitazone | 56 | 195 |
| XENDOS | Orlistat | 37 | 29 |
| DREAM | Rosiglitazone | 60 | 122 |
| Ramipril | No effect | ||
| NAVIGATOR | Nateglinide | No effect | 107 |
| Valsartan | 14 | 199 | |
| Trials in Progress | |||
| ORIGIN | Insulin, glargine, ω-3 fatty acids | Ongoing |
NAVIGATOR indicates Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research.